Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedincellMDCLF +393.00%77 Days Sales Outstanding is 19.44 as of Mar. 2026, which is 66% below its 10-year median of 56.77. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 836 Biotechnology companies, Medincell ranks better than 88.64% on this metric.
Medincell's average Accounts Receivable for the
six
months ended in Mar. 2026 was $0.97 Mil. Medincell's Revenue for the
six
months ended in Mar. 2026 was $9.15 Mil.
Hence, Medincell's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 19.44.
The historical rank and industry rank for Medincell's Days Sales Outstanding or its related term are showing as below:
MDCLF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.66 Med: 56.77 Max: 75.05
Current: 21.4
During the past 11 years, Medincell's highest Days Sales Outstanding was 75.05. The lowest was 20.66. And the median was 56.77.
MDCLF's Days Sales Outstanding is ranked better than 88.64% of 836
companies
in the Biotechnology industry
Industry Median: 68.725
vs MDCLF: 21.40
Medincell's Days Sales Outstanding
increased
from Mar. 2025 (14.21) to Mar. 2026 (19.44).
Medincell (OTCPK:MDCLF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Medincell Days Sales Outstanding Related Terms
Medincell Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Medincell's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDCLF vs VRTX, REGN, ALNY: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Medincell's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medincell Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medincell's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Medincell's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medincell (MDCLF) has a Days Sales Outstanding of 19.44 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Medincell and its competitors. This is 66% below median its historical median of 56.77. Over the past decade, Medincell's Days Sales Outstanding has ranged from 20.66 to 75.05. According to the industry distribution chart, Medincell ranks #95 out of 836 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Medincell's Days Sales Outstanding too high?
Medincell's current Days Sales Outstanding of 19.44 is 66% below median its 10-year median of 56.77. Over the past 10 years, this metric has ranged from a low of 20.66 to a high of 75.05. The Biotechnology industry median Days Sales Outstanding is 68.73. Medincell's value of 19.44 is 71.7% below this industry median. Based on the distribution chart, Medincell ranks #95 out of 836 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #95 out of 836 companies for Days Sales Outstanding. This places Medincell in the top 11% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.73. Medincell's value of 19.44 is 71.7% below this benchmark. Historically, Medincell's own Days Sales Outstanding has ranged from 20.66 to 75.05 over the past decade. While the company's 10-year median is 56.77 vs. the industry median of 68.73, Medincell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.73, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medincell's current Days Sales Outstanding of 19.44 is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Medincell and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medincell's current Days Sales Outstanding is 19.44, which is 66% below median its own 10-year median of 56.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Days Sales Outstanding of 19.44. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Days Sales Outstanding is 19.44, which is 66% below median its 10-year median of 56.77 and 71.7% below the Biotechnology industry median of 68.73. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Medincell (MDCLF), the current Days Sales Outstanding is 19.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medincell (MDCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Medincell stock appears to be overvalued.
The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.
Key valuation signals for MDCLF:
Days Sales Outstanding: 19.44 (66% below median its 10-year median of 56.77)
GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
Industry Position: 71.7% below the Biotechnology median (#95 of 836)
No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score
Get the complete analysis for MDCLF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDCLF has been successfully added to your 
